Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 4,432 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 4,432 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $40.43, for a total value of $179,185.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Harold Bernstein also recently made the following trade(s):

• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total value of $16,480.00.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Trading Down 0.7%

Shares of MAZE stock traded down $0.26 on Tuesday, reaching $38.37. The company’s stock had a trading volume of 241,160 shares, compared to its average volume of 330,787. The stock’s fifty day simple moving average is $37.15 and its 200-day simple moving average is $25.26. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $43.29. The company has a market capitalization of $1.85 billion and a price-to-earnings ratio of -1.84.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. BTIG Research increased their price target on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Raymond James Financial started coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $43.38.

Institutional Trading of Maze Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. purchased a new position in Maze Therapeutics during the 1st quarter valued at about $226,000. Goldman Sachs Group Inc. purchased a new position in Maze Therapeutics during the first quarter valued at approximately $145,000. Ensign Peak Advisors Inc bought a new position in Maze Therapeutics in the second quarter worth approximately $227,000. Frazier Life Sciences Management L.P. lifted its holdings in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares during the period. Finally, Nuveen LLC purchased a new stake in Maze Therapeutics during the first quarter worth $125,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.